Finanzen von Freenome, Inc. Common stock (FRNM)FRNMFreenome, Inc. Common stock

Evaluating the bottom line, Freenome, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -0.92%, provide a clear picture of how effectively FRNM converts its operational activities into shareholder value.

In the context of the broader market, FRNM competes directly with industry leaders such as BWAY and CNMD. With a market capitalization of $1.51B, it holds a leading position in the sector. When comparing efficiency, FRNM's gross margin of N/A stands against BWAY's 74.62% and CNMD's 57.49%. Such benchmarking helps identify whether Freenome, Inc. is trading at a premium or discount relative to its financial performance.

Freenome has shown fluctuating net income, with a significant loss of -740568.00 USD in Q4 2025, but recent FDA approval may lead to improved financials moving forward.